Altimmune Stock Buy Hold or Sell Recommendation


USD 9.09  0.22  2.36%   

Considering the 90-day investment horizon and your bold attitude towards risk, our recommendation regarding Altimmune is 'Strong Hold'. Macroaxis provides Altimmune buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ALT positions. The advice algorithm takes into account all of Altimmune's available fundamental, technical, and predictive indicators you will find on this site.
The advice is provided from Altimmune's buy-and-hold perspective. Please continue to Altimmune Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Altimmune and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Altimmune.

Execute Altimmune Buy or Sell Advice

The Altimmune recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Altimmune. Macroaxis does not own or have any residual interests in Altimmune or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Altimmune's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell AltimmuneBuy Altimmune
Strong Hold



Hype Condition


Current Valuation


Odds of Distress


Economic Sensitivity


Analyst Consensus


Financial Strenth (F Score)


Financial Leverage


Reporting Quality (M-Score)

For the selected time horizon Altimmune has a Risk Adjusted Performance of (0.21), Jensen Alpha of (1.02), Total Risk Alpha of (1.22) and Treynor Ratio of (0.77)
We provide trade advice to complement the prevailing expert consensus on Altimmune. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Altimmune is not overpriced, please confirm all Altimmune fundamentals, including its earnings per share, one year return, and the relationship between the debt to equity and retained earnings . Given that Altimmune has a price to sales of 101.08 X, we suggest you to validate Altimmune market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Altimmune Trading Alerts and Improvement Suggestions

Altimmune generated a negative expected return over the last 90 days
Altimmune has high historical volatility and very poor performance
The company reported the last year's revenue of 3.48 M. Reported Net Loss for the year was (96.94 M) with loss before taxes, overhead, and interest of (71.09 M).
Altimmune has about 184.76 M in cash with (69.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81.
Altimmune has a frail financial position based on the latest SEC disclosures
Over 82.0% of the company shares are held by institutions such as insurance companies

Altimmune current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Altimmune analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Altimmune analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price29.14
Target Median Price26.00
Target High Price50.00
Recommendation Mean1.70
Number Of Analyst Opinions7
Target Low Price14.00
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Altimmune Returns Distribution Density

The distribution of Altimmune's historical returns is an attempt to chart the uncertainty of Altimmune's future price movements. The chart of the probability distribution of Altimmune stock daily returns describes the distribution of returns around its average expected value. We use Altimmune price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Altimmune returns is essential to provide solid investment advice for Altimmune.
Mean Return-0.93Value At Risk-8.88
Potential Upside8.38Standard Deviation6.19
   Return Density   
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Altimmune historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Altimmune Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Altimmune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Altimmune backward and forwards among themselves. Altimmune's institutional investor refers to the entity that pools money to purchase Altimmune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Xtx Topco LtdCommon Shares19.7 K120 K
Xtx Topco LtdCommon Shares14.8 K135 K
Woodline Partners LpCommon Shares550.7 K6.4 M
Woodline Partners LpCommon Shares846.6 K5.2 M
Woodline Partners LpCommon Shares620.7 K5.7 M
Woodline Partners LpCommon Shares348.8 K3.9 M
Wolverine Trading LlcCommon Shares24.1 K284 K
Wolverine Trading LlcCall Options29.8 K351 K
Wolverine Trading LlcPut Options41.6 K371 K
Note, although Altimmune's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Altimmune Cash Flow Accounts

201720182019202020212022 (projected)
Capital Expenditure(158.69 K)(1 M)(1.23 K)(203.96 K)(12.12 M)(12.44 M)
Depreciation Amortization and Accretion139.02 K302.37 K387.32 K428.88 K551.3 K457.7 K
Net Cash Flow or Change in Cash and Cash Equivalents9.43 M22.05 M(25.36 M)106.96 M74.38 M80.26 M
Issuance Purchase of Equity Shares16.45 K37.43 M12.7 M213.49 M65.22 M53.3 M
Issuance Repayment of Debt Securities(80.57 K)2.81 M(1.55 M)(292 K)(262.8 K)(269.72 K)
Net Cash Flow from Financing15.84 M32.49 M12.53 M213.49 M65.1 M70.24 M
Net Cash Flow from Investing13.73 M(1 M)(28.29 M)(72.09 M)87.52 M94.43 M
Net Cash Flow from Operations(20.21 M)(9.39 M)(9.6 M)(34.44 M)(78.24 M)(80.3 M)
Effect of Exchange Rate Changes on Cash(1.77 K)(171.54 K)74.39 K(50.37 K)(57.92 K)(62.49 K)
Share Based Compensation1.44 M773.25 K1.26 M2.58 M5.52 M5.95 M

Altimmune Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Altimmune or iShares sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Altimmune's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Altimmune stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Alpha over DOW
Beta against DOW1.23
Overall volatility
Information ratio -0.16

Altimmune Volatility Alert

Altimmune is displaying above-average volatility over the selected time horizon. Investors should scrutinize Altimmune independently to ensure intended market timing strategies are aligned with expectations about Altimmune volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Altimmune's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Altimmune's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Altimmune Fundamentals Vs Peers

Comparing Altimmune's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Altimmune's direct or indirect competition across all of the common fundamentals between Altimmune and the related equities. This way, we can detect undervalued stocks with similar characteristics as Altimmune or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Altimmune's fundamental indicators could also be used in its relative valuation, which is a method of valuing Altimmune by comparing valuation metrics with those of similar companies.
 Better Than Average     
 Worse Than Average Compare Altimmune to competition
FundamentalsAltimmunePeer Average
Return On Equity(44.49) %(0.31) %
Return On Asset(24.85) %(0.14) %
Current Valuation366.1 M16.62 B
Shares Outstanding39.74 M571.82 M
Shares Owned by Insiders0.71 %10.09 %
Shares Owned by Institutions82.27 %39.21 %
Number of Shares Shorted7.05 M4.71 M
Price to Earning(1.66) X28.72 X
Price to Book1.45 X9.51 X
Price to Sales101.08 X11.42 X
Revenue3.48 M9.43 B
Gross Profit(71.09 M)27.38 B
EBITDA(92.3 M)3.9 B
Net Income(96.94 M)570.98 M
Cash and Equivalents184.76 M2.7 B
Cash per Share3.81 X5.01 X
Total Debt1.33 M5.32 B
Debt to Equity0.006 %48.70 %
Current Ratio14.12 X2.16 X
Book Value Per Share6.11 X1.93 K
Cash Flow from Operations(69.97 M)971.22 M
Short Ratio1.67 X4.00 X
Earnings Per Share(1.91) X3.12 X
Number of Employees4718.84 K
Market Capitalization351.29 M19.03 B
Total Asset29.47 M29.47 B
Retained Earnings(148.22 M)9.33 B
Working Capital5 M1.48 B
Current Asset13.9 M9.34 B
Current Liabilities10.49 M7.9 B
Year to Date Return1.67 %
One Year Return(6.49) %
   Payment of 3008 shares by Vipin Garg of Altimmune subject to Rule 16b-3 [view details]

Altimmune Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Altimmune . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Altimmune Buy or Sell Advice

When is the right time to buy or sell Altimmune? Buying financial instruments such as Altimmune Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2019 2020 2021 2022 (projected)
Accounts Payable18.23 K612.29 K2.03 M1.67 M
Receivables1.02 M4.61 M5.84 M5.45 M

Use Investing Ideas to Build Portfolios

In addition to having Altimmune in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Plastics Thematic Idea Now

Plastics Theme
Companies manufacturing rubber and plastics accessories. The Plastics theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Plastics Theme or any other thematic opportunities.
View All  Next Launch
Please continue to Altimmune Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for analysis

When running Altimmune price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Bond Directory
Find actively traded corporate debentures issued by US companies
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
441.4 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine Altimmune value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.